Literature DB >> 11516871

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low.

C R King1, J F Fowler.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11516871     DOI： 10.1016/s0360-3016(01)01651-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  28 in total

Review 1.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Authors:  Alan Pollack; Alex Hanlon; Eric M Horwitz; Steven Feigenberg; Robert G Uzzo; Robert A Price
Journal:  World J Urol       Date:  2003-09-05       Impact factor: 4.226

2.  Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

Authors:  Jeffrey V Brower; Jeffrey D Forman; Patrick A Kupelian; Daniel G Petereit; Vinai Gondi; Colleen A Lawton; Nick Anger; Sandeep Saha; Rick Chappell; Mark A Ritter
Journal:  Radiother Oncol       Date:  2016-01-02       Impact factor: 6.280

3.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

Review 4.  Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations.

Authors:  Nicholas J Sanfilippo; Benjamin T Cooper
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

5.  Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

Authors:  Jeff M Michalski; Kyounghwa Bae; Mack Roach; Arnold M Markoe; Howard M Sandler; Janice Ryu; Matthew B Parliament; William Straube; Richard K Valicenti; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

Review 6.  Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy.

Authors:  Scott G Williams; Anthony L Zietman
Journal:  World J Urol       Date:  2008-09-07       Impact factor: 4.226

7.  Endo-rectal balloon cavity dosimetry in a phantom: performance under IMRT and helical tomotherapy beams.

Authors:  Nicholas Hardcastle; Peter E Metcalfe; Anatoly B Rosenfeld; Wolfgang A Tomé
Journal:  Radiother Oncol       Date:  2009-03-30       Impact factor: 6.280

8.  Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre.

Authors:  J Valero; A Montero; O Hernando; M Izquierdo; E Sánchez; M García-Aranda; M López; R Ciérvide; J Martí; B Álvarez; R Alonso; X Chen-Zhao; P Fernández-Letón; C Rubio
Journal:  Clin Transl Oncol       Date:  2021-01-12       Impact factor: 3.405

9.  Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment.

Authors:  Gustavo Arruda Viani; Lucas Bernardes Godoy da Silva; Bruna Bueno da Silva; Yuri Bonicelli Crempe; Vinicius Spazzapan Martins; Ricardo Jose Rambaiolo Ferrari; Mariana Colbachini Pólo; Bruno Thiago Rossi; Elton Suguikawa; Giseli Correa Zulliani; Eduardo Jose Stefano
Journal:  Radiat Oncol       Date:  2013-04-21       Impact factor: 3.481

10.  Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy.

Authors:  Courtney Knaup; Panayiotis Mavroidis; Sotirios Stathakis; Mark Smith; Gregory Swanson; Niko Papanikolaou
Journal:  J Contemp Brachytherapy       Date:  2011-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.